Stay updated on Sitravatinib in Hepatic Impairment Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib in Hepatic Impairment Clinical Trial page.

Latest updates to the Sitravatinib in Hepatic Impairment Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded a consolidated Locations section and removed state-specific location entries (California, Florida, Minnesota, Texas) as part of a revision, and removed the HHS Vulnerability Disclosure link.SummaryDifference0.6%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 with no changes to core page content or user-facing details.SummaryDifference0.1%

- Check54 days agoChange DetectedA government funding status notice was removed from the page, eliminating updates about potential delays in information and site operations. Core study details and eligibility criteria remain unchanged.SummaryDifference0.4%

- Check68 days agoChange DetectedCore study details (eligibility criteria, primary/secondary outcomes, enrollment, locations) appear unchanged; the changes observed are cosmetic/layout adjustments to the page presentation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check97 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference4%

- Check104 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Sitravatinib in Hepatic Impairment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib in Hepatic Impairment Clinical Trial page.